Neparvis (Valsartan, Sacubitril)

Neparvis (sacubitril/valsartan) is indicated for cardiovascular conditions that benefit from combined angiotensin receptor blockade and neprilysin inhibition.

• Heart failure with reduced ejection fraction: improves survival and reduces hospital admissions.
• Hypertension: lowers systolic and diastolic blood pressure when monotherapy or combination therapy is required.

• Sacubitril/valsartan combines valsartan, which blocks angiotensin II type 1 receptors, with sacubitril, a neprilysin inhibitor that prevents degradation of natriuretic peptides. This dual action enhances vasodilation, natriuresis, and reduces cardiac remodeling, leading to improved hemodynamic status in heart failure and lower blood pressure in hypertension.

Neparvis may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Hypotension: symptomatic low blood pressure, often orthostatic.
• Hyperkalaemia: elevated serum potassium levels.
• Cough: mild to moderate respiratory irritation.
• Fatigue: generalized tiredness.
• Renal impairment: rise in serum creatinine.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or airway.
• Severe hypotension: marked drop in blood pressure requiring medical intervention.
• Hepatic injury: abnormal liver enzymes or jaundice.
• Myocardial infarction: rare occurrence of acute coronary syndrome.
• Anaphylaxis: life‑threatening allergic reaction.
• Acute kidney injury: sudden loss of renal function.

Before initiating Neparvis, clinicians should evaluate patient-specific factors and monitor relevant parameters.

• Blood pressure monitoring: check for hypotension after each dose adjustment.
• Renal function: assess serum creatinine and eGFR regularly.
• Electrolytes: monitor potassium levels to avoid hyperkalaemia.
• History of angioedema: avoid use in patients with prior episodes.
• Concomitant ACE inhibitors: ensure a 36‑hour washout period to reduce angioedema risk.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Neparvis interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• ACE inhibitors: concurrent use increases risk of angioedema.
• Aliskiren in diabetic patients: may cause severe hypotension and renal dysfunction.
• Potassium‑sparing diuretics: can precipitate dangerous hyperkalaemia.
• NSAIDs: may impair renal function and blunt antihypertensive effect.
• Strong CYP3A4 inhibitors: can increase sacubitril exposure.

Moderate Interactions (Monitor Closely)

• Loop diuretics: additive blood‑pressure lowering; monitor volume status.
• Lithium: risk of lithium toxicity; check serum levels.
• Other antihypertensives: may require dose adjustments to avoid excessive hypotension.
• Rifampin: may reduce sacubitril/valsartan plasma concentrations.
• Antidiabetic agents: monitor glucose control as blood‑pressure changes can affect insulin sensitivity.